Cuilin Zhang
Cuilin Zhang is a senior investigator in the Division of Intramural Population Health Research at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). She is known for her research in the field of epidemiology, particularly in relation to gestational diabetes and its long-term effects on women's health.
Education and Career[edit | edit source]
Zhang received her MD from Peking University Health Science Center in Beijing, China, and her PhD in Epidemiology from the University of Washington. She completed her postdoctoral training at the Harvard School of Public Health.
In 2008, Zhang joined the NICHD as a tenure-track investigator. She was promoted to senior investigator in 2014. Her research focuses on the epidemiology of gestational diabetes mellitus (GDM) and its long-term effects on women's health.
Research[edit | edit source]
Zhang's research has significantly contributed to the understanding of the epidemiology of GDM. She has conducted several large cohort studies investigating the risk factors and long-term consequences of GDM. Her work has shown that GDM is associated with an increased risk of type 2 diabetes and cardiovascular disease in women later in life.
Zhang has also conducted research on the effects of lifestyle interventions on the prevention of GDM and its long-term consequences. Her work has shown that lifestyle interventions can reduce the risk of GDM and improve long-term health outcomes for women.
Awards and Honors[edit | edit source]
Zhang has received several awards for her research, including the NICHD Director's Award and the American Diabetes Association's Norbert Freinkel Award.
References[edit | edit source]
External Links[edit | edit source]
- Cuilin Zhang at the NIH Intramural Research Program
Cuilin Zhang Resources | ||
---|---|---|
|
|
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD